/

Empresas

Al

No verificado

Almirall

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaIndustriaSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa

11/05/2026

Mercado de valores

Acciones y Obligaciones

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business

Fuente

Editor

1.00

0

13/04/2026

Mercado laboral

Industria

Ciencia

Técnica

Asociaciones/Profesionales

Biotecnología

Salud

Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology

Fuente

Editor

1.00

0

23/03/2026

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Psiquiatría

Sanidad

Eventos

Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology

Fuente

Editor

1.00

0

16/03/2026

Ciencia

Jóvenes

Infancia

Medicina - Varios

Familia

Biotecnología

Farmacéutica

Ir de compras

Salud

Industria

Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis

Fuente

Editor

1.00

0

21/03/2025

Eventos

Ciencia

Biotecnología

Farmacéutica

Sanidad

Oncología

Salud

Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology

Fuente

Editor

1.00

0

14/01/2025

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Fuente

Editor

1.00

0

04/12/2024

Multimedia

Industria

Sanidad

Ciencia

Asociaciones/Profesionales

Psiquiatría

Biotecnología

Salud

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Fuente

Editor

1.00

0

25/09/2024

Multimedia

Industria

Eventos

Biotecnología

Farmacéutica

Finanzas

Sanidad

Salud

Asociaciones/Profesionales

Medicina - Varios

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Fuente

Editor

1.00

0

23/09/2024

Industria

Eventos

Biotecnología

Sanidad

Salud

Farmacéutica

Medicina - Varios

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Fuente

Editor

1.00

0

02/07/2024

Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0